INTRODUCTION: Squamous cell carcinoma of the anus (SCCA) is a relatively uncommon cancer. In the HIV-Positive patients the introduction of the highly active antiretroviral therapy (HAART) did not change the incidence of SCCA. BACKGROUND AND OBJECTIVES: This paper describes the Italian Cooperative Group on AIDS and Tumours (GICAT) experience on HIV-Positive patients with SCCA. The purposes of this retrospective study were: First to describe the clinical presentation and outcome of HIV-Positive patients with SCCA, second to compare them with the ones reported in the literature. PATIENTS AND METHODS: Between July 2000 and March 2010 we retrospectively collected epidemiological, clinical and survival data from 65 patients with SCCA in HIV infection enrolled within the GICAT. RESULTS: Fifty-Three (81.5%) patients were male. The majority of patients (40%) were homosexual Forty-Three patients (66.1%) were diagnosed with HIV before 1996. Thirty-Five patients (54%) had CD4-Positive cells count >200/mm3 and 28 patients (43%) had viral load >50 cp/ml at the time of SCCA diagnosis. The median time difference between HIV and SCCA diagnosis was 120 months (range 10-282 months). Sixty-One patients (96.8%) received HAART at SCCA diagnosis. Fiftytwo patients (80%) had performance status (PS) 0-1 at the time of SCCA diagnosis. Twenty-Seven patients (41.5%) underwent surgery with curative intent. Thirty-Five patients (53.9%) were given combined modality therapy (CMT) consisting of pelvic radiotherapy with concurrent chemotherapy. No grade 3/4 haematological or extra-Haematological effects were observed in our patients. CONCLUSIONS: In summary, despite the retrospective nature of analysis, the absence of patient strict criteria of inclusion/exclusion, our data on HIV-Positive patients with SCCA, compared both to general population and to small reports on HIV-Positive patients present in the literature, are promising.
Clinical presentation and outcome of squamous cell carcinoma of the anus in HIV-Infected patients in the HAART-Era: A gicat experience
Berretta M.Secondo
;
2012-01-01
Abstract
INTRODUCTION: Squamous cell carcinoma of the anus (SCCA) is a relatively uncommon cancer. In the HIV-Positive patients the introduction of the highly active antiretroviral therapy (HAART) did not change the incidence of SCCA. BACKGROUND AND OBJECTIVES: This paper describes the Italian Cooperative Group on AIDS and Tumours (GICAT) experience on HIV-Positive patients with SCCA. The purposes of this retrospective study were: First to describe the clinical presentation and outcome of HIV-Positive patients with SCCA, second to compare them with the ones reported in the literature. PATIENTS AND METHODS: Between July 2000 and March 2010 we retrospectively collected epidemiological, clinical and survival data from 65 patients with SCCA in HIV infection enrolled within the GICAT. RESULTS: Fifty-Three (81.5%) patients were male. The majority of patients (40%) were homosexual Forty-Three patients (66.1%) were diagnosed with HIV before 1996. Thirty-Five patients (54%) had CD4-Positive cells count >200/mm3 and 28 patients (43%) had viral load >50 cp/ml at the time of SCCA diagnosis. The median time difference between HIV and SCCA diagnosis was 120 months (range 10-282 months). Sixty-One patients (96.8%) received HAART at SCCA diagnosis. Fiftytwo patients (80%) had performance status (PS) 0-1 at the time of SCCA diagnosis. Twenty-Seven patients (41.5%) underwent surgery with curative intent. Thirty-Five patients (53.9%) were given combined modality therapy (CMT) consisting of pelvic radiotherapy with concurrent chemotherapy. No grade 3/4 haematological or extra-Haematological effects were observed in our patients. CONCLUSIONS: In summary, despite the retrospective nature of analysis, the absence of patient strict criteria of inclusion/exclusion, our data on HIV-Positive patients with SCCA, compared both to general population and to small reports on HIV-Positive patients present in the literature, are promising.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
